{"log_id": 6328530686221254590, "direction": 0, "words_result_num": 30, "words_result": [{"probability": {"variance": 0.004878, "average": 0.976353, "min": 0.599148}, "location": {"width": 995, "top": 117, "height": 40, "left": 117}, "words": "注:FAS:全分析集;mOS:中位总生存期;mPFS:中位无进展生存期:CR:完全缓解;PR:部分缓解;"}, {"probability": {"variance": 0.007827, "average": 0.956692, "min": 0.740884}, "location": {"width": 131, "top": 170, "height": 26, "left": 122}, "words": "SD:疾病稳定"}, {"probability": {"variance": 6.1e-05, "average": 0.993522, "min": 0.977536}, "location": {"width": 132, "top": 204, "height": 29, "left": 127}, "words": "【药理毒理】"}, {"probability": {"variance": 1e-06, "average": 0.998294, "min": 0.996994}, "location": {"width": 100, "top": 253, "height": 31, "left": 168}, "words": "药理作用"}, {"probability": {"variance": 5.8e-05, "average": 0.996642, "min": 0.956175}, "location": {"width": 944, "top": 295, "height": 38, "left": 169}, "words": "作用机制:本品为一种小分子血管内皮细胞生长因子受体2( VEGFR-2)酪氨酸激酶抑制"}, {"probability": {"variance": 3e-06, "average": 0.998801, "min": 0.993354}, "location": {"width": 930, "top": 342, "height": 40, "left": 118}, "words": "剂,可抑制肿瘤血管生成。动物研究表明本品可明显抑制多种小鼠肿瘤模型的肿瘤生长"}, {"probability": {"variance": 0, "average": 0.999583, "min": 0.999038}, "location": {"width": 102, "top": 398, "height": 29, "left": 168}, "words": "毒理研究"}, {"probability": {"variance": 0.00031, "average": 0.996057, "min": 0.87967}, "location": {"width": 948, "top": 437, "height": 40, "left": 167}, "words": "长期毒性:大鼠26周长期毒性研究(5,15,50mg/kg/天)显示本品无毒性反应剂量为5"}, {"probability": {"variance": 0.000237, "average": 0.993955, "min": 0.900106}, "location": {"width": 959, "top": 485, "height": 42, "left": 122}, "words": "mg/kg(雌鼠)和15mg/kg(雄鼠)。毒性反应剂量为15mg/kg(雌鼠)和50mg/kg(雄鼠)"}, {"probability": {"variance": 3.2e-05, "average": 0.998625, "min": 0.963163}, "location": {"width": 993, "top": 533, "height": 40, "left": 120}, "words": "毒性反应包括雌性大鼠白细胞升高及提前出现早期慢性进行性肾病样的形态学改变;雌雄大鼠"}, {"probability": {"variance": 0.002796, "average": 0.990482, "min": 0.656805}, "location": {"width": 994, "top": 579, "height": 42, "left": 120}, "words": "红系改变、切齿断裂、耗食量下降及肝肾功能的轻度改变,除切齿的改变未能完全恢复外,其"}, {"probability": {"variance": 0.000303, "average": 0.994688, "min": 0.881956}, "location": {"width": 992, "top": 630, "height": 38, "left": 122}, "words": "它改变在停药后基本恢复;犬39周长期毒性研究(20,60,120mg/kg/天)显示,仅20mg/kg"}, {"probability": {"variance": 0.000115, "average": 0.996621, "min": 0.932903}, "location": {"width": 996, "top": 676, "height": 39, "left": 118}, "words": "1条雄性犬精子生成障碍,其它均未见药物相关性的变化,恢复期也未见异常改变,剂量≤20"}, {"probability": {"variance": 1.5e-05, "average": 0.996807, "min": 0.988049}, "location": {"width": 191, "top": 731, "height": 31, "left": 123}, "words": "mg/kg为安全剂量"}, {"probability": {"variance": 6e-06, "average": 0.998676, "min": 0.991569}, "location": {"width": 946, "top": 771, "height": 38, "left": 168}, "words": "遗传毒性:鼠伤寒沙门氏菌回复突变试验、中国仓鼠肺成纤维细胞染色体畸变试验、小鼠"}, {"probability": {"variance": 0.00024, "average": 0.994025, "min": 0.939522}, "location": {"width": 442, "top": 821, "height": 41, "left": 49}, "words": "骨髓微核试验显示本品无遗传毒性"}, {"probability": {"variance": 8e-06, "average": 0.998104, "min": 0.985054}, "location": {"width": 946, "top": 867, "height": 38, "left": 169}, "words": "生殖毒性:SD大鼠于妊娠第6~15天灌胃给予本品16mg/kg天,有一定程度的胚胎胎仔"}, {"probability": {"variance": 0.000499, "average": 0.993859, "min": 0.857483}, "location": {"width": 993, "top": 915, "height": 36, "left": 122}, "words": "毒性,可使胎鼠骨骼发育延迟并有致畸效应,但无母体毒性。对胚胎-胎仔无毒性作用的剂量"}, {"probability": {"variance": 3e-06, "average": 0.997799, "min": 0.994553}, "location": {"width": 113, "top": 970, "height": 29, "left": 122}, "words": "为4mg/kg"}, {"probability": {"variance": 0, "average": 0.737154, "min": 0.737154}, "location": {"width": 110, "top": 979, "height": 49, "left": 804}, "words": "药"}, {"probability": {"variance": 2.1e-05, "average": 0.997883, "min": 0.983525}, "location": {"width": 275, "top": 1013, "height": 34, "left": 168}, "words": "本品尚未进行致癌性研究"}, {"probability": {"variance": 1e-06, "average": 0.999304, "min": 0.997281}, "location": {"width": 158, "top": 1065, "height": 28, "left": 130}, "words": "【药代动力学】"}, {"probability": {"variance": 3.6e-05, "average": 0.997837, "min": 0.962493}, "location": {"width": 946, "top": 1115, "height": 41, "left": 170}, "words": "本品在36例健康受试者和52例转移性实体瘤患者进行了不同剂量单次和多次给药的药代"}, {"probability": {"variance": 0, "average": 0.999646, "min": 0.999332}, "location": {"width": 125, "top": 1178, "height": 31, "left": 121}, "words": "动力学研究"}, {"probability": {"variance": 0.000821, "average": 0.971329, "min": 0.942679}, "location": {"width": 52, "top": 1234, "height": 25, "left": 170}, "words": "吸收"}, {"probability": {"variance": 0.000109, "average": 0.995315, "min": 0.941856}, "location": {"width": 952, "top": 1279, "height": 39, "left": 165}, "words": "健康受试者单次空腹口服250mg,500mg和750mg后,在体内吸收较快,原形药血浆浓度"}, {"probability": {"variance": 0.002571, "average": 0.983568, "min": 0.683189}, "location": {"width": 995, "top": 1333, "height": 40, "left": 124}, "words": "平均达峰时间约为1.7~2.3h;消除较慢,平均消除半衰期为7.9~9.4h。在250mg和500mg剂"}, {"probability": {"variance": 2.7e-05, "average": 0.997537, "min": 0.968377}, "location": {"width": 969, "top": 1388, "height": 40, "left": 124}, "words": "量组,原形药物血浆暴露量与剂量成正比例,750mg剂量组原形药的暴露量未见进一步增加"}, {"probability": {"variance": 7e-06, "average": 0.998328, "min": 0.98984}, "location": {"width": 531, "top": 1448, "height": 36, "left": 124}, "words": "未见明显性别差异。具体各药代动力学参数见表5"}, {"probability": {"variance": 0.000985, "average": 0.990913, "min": 0.8456}, "location": {"width": 802, "top": 1502, "height": 34, "left": 163}, "words": "表5.健康受试者单次空腹口服250mg、500mg和750mg阿帕替尼片的药代动力学参数"}], "language": 3}